Results: Blocking BCL2, we observed reduced proliferation and clonogenic potential of CML CD34-positive cells and this cytotoxicity was improved by combination with BCR-ABL1 inhibitor. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.